PPT-Darunavir/r versus Other PIs in Treatment Experienced

Author : nasir | Published Date : 2024-09-18

POWER 1 and 2 Darunavir r versus other PIs in TreatmentExperienced POWER 1 and 2 Study Design Source Clotet B et al Lancet 2007369 116978 Darunavir BID RTV

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Darunavir/r versus Other PIs in Treatmen..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Darunavir/r versus Other PIs in Treatment Experienced: Transcript

POWER 1 and 2 Darunavir r versus other PIs in TreatmentExperienced POWER 1 and 2 Study Design Source Clotet B et al Lancet 2007369 116978 Darunavir BID RTV BID OBR . SIRIUS. Phase . 2 . Treatment. . Experienced. Bourliere. M, et al. Lancet Infect Dis. . 2015;15:397-404.. Source: . Bourliere. . M, . et al. . Lancet Infect Dis. 2015;15:397-404.. Ledipasvir-Sofosbuvir in Treatment-Experienced . . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . Evidence-Based Approaches. Simply Speaking. ®. HIV “Essentials for Optimal Care of HIV Patients: Evidence-Based Approaches” is. Copyrighted 2018 by Practice Point Communications, unless otherwise noted. All rights reserved.. By. Bani Tamraz, . Pharm.D. ., Ph.D.. Associate Clinical Professor. School of Pharmacy. Research Interests. Identification of . genetic . determinants of drug response. Translate to new diagnostics and treatment strategies . BRIGHTE Study (Week 48 Data). Fostemsavir (FTR) for Heavily Treatment Experienced. BRIGHTE Study . (Week 48). : Background. Source: . Kozal. M, et al. N . Engl. J Med. 2020;382:1232-43.. Study Design: BRIGHTE. PROTEA Trial. Darunavir/r . M. onotherapy. versus Triple Therapy . PROTEA. : Study Design. Source: . Antinori. A, et al. . J Int AIDS Soc. 2014;17:19525.. Darunavir 800 mg QD. + Ritonavir 100 mg . QD. DUAL-GESIDA. Dual Maintenance ART with RTV-Boosted Darunavir + . Lamivudine. DUAL . GESIDA: . Study Design. Source: . Pulido. . F, . et al. . Clin Infect . Dis.. . 2017;65:2112-8.. DRV + RTV + 3TC. Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . POTENT Trial. Tipranavir. /. r . versus Darunavir. /r . in Treatment-Experienced . POTENT. : Study Design. Source: . Elgadi. MM, et al. . Drugs R D. . 2011;11:. 295-. 302.. Tipranavir. . + . R. itonavir BID . DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs. DRIVE FORWARD: Design. Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.. Doravirine. + 2 NRTIs. (n = 385). Darunavir + RTV + 2 NRTIs. RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID . NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC. NEAT001/ANRS143: Study Design. Source: . Raffi. F, et al. Lancet. 2014;384:1942-51. .. Darunavir + Ritonavir QD. + Raltegravir BID . HIV-NAT . 017. SQV and . LPV-RTV . in Treatment-Experienced Children . HIV-NAT . 017: . Study . Design. Source: . Kosalaraksa. P, et al. . Pediatr. Infect Dis J. . 2008;27:. 623-8. . SQV + LPV-RTV +/- 3TC.

Download Document

Here is the link to download the presentation.
"Darunavir/r versus Other PIs in Treatment Experienced"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.